Last reviewed · How we verify
Teriparatide (PF708)
Teriparatide is a recombinant form of parathyroid hormone used to treat osteoporosis by stimulating bone growth.
Teriparatide is a recombinant form of parathyroid hormone used to treat osteoporosis by stimulating bone growth. Used for Treatment of osteoporosis in postmenopausal women and men with a high risk of fractures.
At a glance
| Generic name | Teriparatide (PF708) |
|---|---|
| Sponsor | Pfenex, Inc |
| Drug class | Parathyroid hormone analog |
| Target | PTH1R |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
It works by mimicking the natural parathyroid hormone, which helps to increase bone formation and decrease bone resorption, leading to an increase in bone mass and density.
Approved indications
- Treatment of osteoporosis in postmenopausal women and men with a high risk of fractures
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Muscle weakness
Key clinical trials
- A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants (PHASE1)
- Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo (PHASE1)
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
- Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury (PHASE2)
- Effect of Mechanical Loading With PTH on Cortical Bone (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid (PHASE4)
- Novel Combination Therapy for Osteoporosis in Men (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teriparatide (PF708) CI brief — competitive landscape report
- Teriparatide (PF708) updates RSS · CI watch RSS
- Pfenex, Inc portfolio CI